Stryker said reported net sales for Q3 2025 increased to $6.1 billion, up 10.3%, and organic net sales increased 9.5%. The company said organic growth included 9.1% from increased unit volume and 0.4% from higher prices.

1. 01

   Stryker said reported net sales for Q3 2025 increased to $6.1 billion, up 10.3%, and organic net sales increased 9.5%. The company said organic growth included 9.1% from increased unit volume and 0.4% from higher prices.

2. 02

   For Q3, the company reported net earnings of $859 million, up 3.0%, and diluted net earnings per share of $2.22. Adjusted EPS increased 11.1% to $3.19, and adjusted operating income margin was 25.6%.

3. 03

   Stryker raised its full-year 2025 guidance and now expects organic net sales growth of 9.8% to 10.2% and adjusted net earnings per diluted share in the range of $13.50 to $13.60. The company said foreign exchange is expected to have a slightly positive impact on both sales and adjusted net earnings per diluted share should rates hold near current levels.

4. 04

   Stryker disclosed that net cash provided by operating activities for the 9 months was $2,901 million, and acquisitions, net of cash acquired, totaled $4,950 million for the same period. Net borrowings for the 9 months were $2,330 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.